"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report



Abstract

Male breast cancer, although rare, is on the rise. Prospective clinical trials are unlikely and current management mirrors that of post-menopausal women. Neoadjuvant chemotherapy is widely used and pathologic complete response (pCR) predicts long-term survival. The addition of dual HER2 (human epidermal growth factor receptor 2) blockade has shown the highest pCR rates; however, there is no published data of this approach in men. Also, newer monitoring tools are necessary during a neoadjuvant therapy to help personalize treatment. 

Here, we describe the case of a 64-year-old man with Stage IIB (tumor size 2 to 5 cm with involvement of axillary lymph nodes), high-grade estrogen receptor, progesterone receptor, and HER2-positive invasive ductal carcinoma with a germline breast cancer susceptibility gene 1 (BRCA1) mutation who was treated in a neoadjuvant fashion with dual HER2 blockade and platinum-based chemotherapy regimen. A novel predictive tool, ultrasound-localized diffuse optical tomography, was used to monitor his progress during treatment.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report


Author Information

Debasmita Saha Corresponding Author

Neag Comprehensive Cancer Center, University of Connecticut Health Center

Susan Tannenbaum

Neag Comprehensive Cancer Center, University of Connecticut Health Center

Quing Zhu

Biomedical Engineering and Radiology, Washington University, St Louis, Mo


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. University of Connecticut Health Center Institutional Review Board issued approval 12-194-6. Ultrasound and Near-Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring. Conflicts of interest: The authors have declared that no conflicts of interest exist.

Acknowledgements

National Institute of Health (NIH RO1EB002136) funded the near infrared imaging study.


Case report
peer-reviewed

Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report


Figures etc.

Share
Case report
peer-reviewed

Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report

  • Author Information
    Debasmita Saha Corresponding Author

    Neag Comprehensive Cancer Center, University of Connecticut Health Center

    Susan Tannenbaum

    Neag Comprehensive Cancer Center, University of Connecticut Health Center

    Quing Zhu

    Biomedical Engineering and Radiology, Washington University, St Louis, Mo


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. University of Connecticut Health Center Institutional Review Board issued approval 12-194-6. Ultrasound and Near-Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring. Conflicts of interest: The authors have declared that no conflicts of interest exist.

    Acknowledgements

    National Institute of Health (NIH RO1EB002136) funded the near infrared imaging study.


    Article Information

    Published: July 17, 2017

    DOI

    10.7759/cureus.1481

    Cite this article as:

    Saha D, Tannenbaum S, Zhu Q (July 17, 2017) Treatment of Male Breast Cancer by Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Response Prediction Using Novel Optical Tomography Imaging: A Case Report. Cureus 9(7): e1481. doi:10.7759/cureus.1481

    Publication history

    Received by Cureus: May 21, 2017
    Peer review began: June 01, 2017
    Peer review concluded: July 07, 2017
    Published: July 17, 2017

    Copyright

    © Copyright 2017
    Saha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Male breast cancer, although rare, is on the rise. Prospective clinical trials are unlikely and current management mirrors that of post-menopausal women. Neoadjuvant chemotherapy is widely used and pathologic complete response (pCR) predicts long-term survival. The addition of dual HER2 (human epidermal growth factor receptor 2) blockade has shown the highest pCR rates; however, there is no published data of this approach in men. Also, newer monitoring tools are necessary during a neoadjuvant therapy to help personalize treatment. 

Here, we describe the case of a 64-year-old man with Stage IIB (tumor size 2 to 5 cm with involvement of axillary lymph nodes), high-grade estrogen receptor, progesterone receptor, and HER2-positive invasive ductal carcinoma with a germline breast cancer susceptibility gene 1 (BRCA1) mutation who was treated in a neoadjuvant fashion with dual HER2 blockade and platinum-based chemotherapy regimen. A novel predictive tool, ultrasound-localized diffuse optical tomography, was used to monitor his progress during treatment.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Debasmita Saha

Neag Comprehensive Cancer Center, University of Connecticut Health Center

For correspondence:
debsmdhk@gmail.com

Susan Tannenbaum

Neag Comprehensive Cancer Center, University of Connecticut Health Center

Quing Zhu

Biomedical Engineering and Radiology, Washington University, St Louis, Mo

Debasmita Saha

Neag Comprehensive Cancer Center, University of Connecticut Health Center

For correspondence:
debsmdhk@gmail.com

Susan Tannenbaum

Neag Comprehensive Cancer Center, University of Connecticut Health Center

Quing Zhu

Biomedical Engineering and Radiology, Washington University, St Louis, Mo